Greece
InMed enrols first adolescent in Phase II epidermolysis bullosa trial
The trial will assess the safety of INM-755 as well as its initial efficacy to treat symptoms and heal wounds over 28 days.
The trial will assess the safety of INM-755 as well as its initial efficacy to treat symptoms and heal wounds over 28 days.